The case for & against
Bull & Bear analysis
Bullish
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is a clinical-stage biopharmaceutical company with a focus on developing innovative therapies for cardiovascular conditions, particularly targeting paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AFib). The company's recent commercial launch of Cardamist, a self-administered treatment for PSVT, marks a significant step in its strategy to address a previously unmet medical need, positioning Milestone within the growing therapeutic landscape of cardiovascular health.
Bull says
- ↑~600 prescriptions plus 400+ positive HCP endorsements highlight early traction.
- ↑$184M cash on hand funds launch and operations into H2 2027.
- ↑Nasal‐spray delivery meets urgent PSVT need, boosting patient satisfaction.
- ↑Express Scripts covers ~25% of insured lives, aiding rapid adoption.
- ↑10M AFib patients annually; Phase III Atripamil trial to expand pipeline.
- ↑Strong liquidity and quality factors contrast with negative profitability.
Bear says
- ↓Q1 2026 net loss $26.1M against $23.7M burn rate.
- ↓Product revenue only $0.2M in Q1, signaling weak initial sales.
- ↓Insurer controls could block over 50% of Cardamist scripts.
- ↓High competition may limit market share and pricing power.
- ↓PBM negotiations risk further delays in patient access.
- ↓Weak profitability factors and downward earnings revisions heighten risk.
Investment themes with MIST
Pharmaceuticals↓ -0.08%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Julian Komar's Best Winners (Screen Results)↓ -0.50%
NVDA · GOOGL · AVGO
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-13-2026bullish
Transcript signals
Bull points
- Cardamist, the brand name for Atripamil, was approved by the FDA on December 12th as the first and only rapid-acting, self-administered prescription therapy for acute PSVT episodes in adults.
- Cardamist became readily available through retail pharmacies by the end of January.
- We expect to enroll our first patient into this trial in the second half of this year and look forward to providing further updates as the Rivera 301 study advances this year.
Bear points
- Net loss for the first quarter of 2026 was approximately $26.1 million, or 20 cents per share, compared to $20.8 million, or 31 cents per share, in the first quarter of 2025.
Read full transcript analysis ›